Stryker Corporation
SYKHealthcareNASDAQMedical Devices · Last scanned Sep 9, 2026
Scan Results
Daily timeframeStryker Corporation operates as a medical technology company in the United States and internationally. With a market capitalization of $106.03B, it sits in large-cap territory. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Market Cap
$106.03B
Beta
0.77
P/E (TTM)
28.68
P/E (Fwd)
16.50
EPS (TTM)
$9.64
EPS (Fwd)
$16.75
ROE
16.5%
ROA
8.2%
Cash
$3.48B
Total Debt
$15.45B
Free CF
$4.11B
52W Change
-20.8%
Annual Financials
Cash vs Debt
Where SYK stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, SYK finished 4.26% below its 150-day moving average ($331.54) and 6.10% below its 200-day moving average ($338.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SYK overbought or oversold?
At the September 2, 2026 close, SYK's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $3.48B in cash, though total debt stands at $15.45B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $4.11B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 16.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $18.45B (2022) to $25.12B (2025), reflecting a 36% increase over the period.
As with any equity investment, SYK carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Stryker Corporation and its sector.